Crestor Significantly Reduced Stroke Risk in Elderly: New Jupiter Analysis

Reuters.com


A new analysis from the JUPITER study showed that CRESTOR((R)) (rosuvastatin calcium) 20mg reduced the composite primary end point of major cardiovascular (CV) events (myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by 39% (p<0.001), compared to placebo, in elderly patients with LDL-C less than 130 mg/dL and elevated high-sensitivity C-reactive protein (hsCRP).  This analysis was conducted in 5,695 patients aged 70 years or older. The results from this analysis are consistent with the CV risk reduction seen across all patients taking rosuvastatin in the primary JUPITER analysis. These data were presented today at the European Society of Cardiology (ESC) meeting in Barcelona, Spain.


Additional results from this analysis showed that treatment with CRESTOR:


  • Reduced the combined risk of cardiovascular death, heart attack and stroke by nearly 40% (p=0.004 vs. placebo)
  • Reduced the risk of heart attack by 45% (p=0.046 vs. placebo) and of stroke by 45% (p=0.023 vs. placebo)
  • Reduced the need for hospitalization for arterial revascularization or unstable angina by 49% (p=0.003 vs. placebo)
  • Treatment effects, relative to placebo, were generally comparable in both the elderly (aged 70 or older) and younger patient groups


"In this study, treatment with CRESTOR significantly reduced the risk of major cardiovascular events in elderly patients," said Alex Gold, MD, Executive Director of Clinical Development for CRESTOR, AstraZeneca US.  "CRESTOR was also well tolerated in patients aged 70 and older, consistent with the other patients in the study."


Read full press release...

 

All active news articles

Get Involved

National Stroke Association’s mission is to reduce the incidence and impact of stroke by developing compelling education and programs focused on prevention, treatment, rehabilitation and support for all impacted by stroke.